Sildenafil and Terazosin interaction

Sildenafil and Terazosin: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.

Moderate

Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.

What the FDA labels say

From the Sildenafil label · effective 2026-07-17

Moderate

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Hypotension when Co-administered with Alpha-blockers or Antihypertensives Alpha-blockers Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Consider the following: Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.

Warnings and precautionsby drug classView label on DailyMed
Moderate

In patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose [see Dosage and Administration ( 2.2 ) ] .

Warnings and precautionsby drug classView label on DailyMed

From the Terazosin (TEZRULY) label · effective 2025-04-18

Moderate

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3).

Warnings and precautionsby drug classView label on DailyMed
Moderate

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phosphodiesterase Type 5 Inhibitors (PDE5-I) Concomitant use of TEZRULY with other anti-hypertensive agents, especially the calcium channel blocker verapamil, can increase the risk of hypotension.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Hypotension has been reported when terazosin has been used with phosphodiesterase-5 (PDE-5) inhibitors.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking TEZRULY.

Warnings and precautionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.